Next generation Syk inhibitors targeting a clinically validated node in human disease
Lucia Bio is developing highly selective spleen tyrosine kinase (Syk) inhibitors for potential application in peripheral immunology, neurology and haematology/oncology.
Lucia Bio, a collaboration between the University of Queensland Emory Drug Discovery Initiative (QEDDI) and Molecule to Medicine (MTM).
Lucia Bio is capitalising on QEDDI’s focused discovery and development of oral small molecule inhibitors of Syk, built on the deep knowledge of Syk and dependent pathways.
Potent and selective Syk inhibitor
An extensive portfolio of molecules with tailored drug-like properties for application in peripheral immunology, neurology and haematology/ oncology.
International project team
Experienced project team assembled with the goal of moving a Syk inhibitor into formal clinical development.
Recent news
Lucia Bio Raises AU$3M in Seed Financing to Advance Best-in-Class Spleen Tyrosine Kinase (Syk) Inhibitors into Clinical Trial Enabling Studies
Fundraising includes new strategic investments by the UniQuest Extension Fund and Uniseed
Proceeds to be used to advance two lead candidates, QED-701 and QED-121, into formal development across neuroinflammatory and autoimmune indications
